| Clinical implications of T cell exhaustion for cancer immunotherapy A Chow, K Perica, CA Klebanoff, JD Wolchok Nature reviews Clinical oncology 19 (12), 775-790, 2022 | 475 | 2022 |
| Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide SR McCurdy, JA Kanakry, MM Showel, HL Tsai, J Bolaños-Meade, ... Blood, The Journal of the American Society of Hematology 125 (19), 3024-3031, 2015 | 332 | 2015 |
| Adoptive T cell immunotherapy for cancer K Perica, JC Varela, M Oelke, J Schneck Rambam Maimonides medical journal 6 (1), e0004, 2015 | 302 | 2015 |
| Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells JC Sunshine, K Perica, JP Schneck, JJ Green Biomaterials 35 (1), 269-277, 2014 | 265 | 2014 |
| Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults YL Kasamon, J Bolaños-Meade, GT Prince, HL Tsai, SR McCurdy, ... Journal of Clinical Oncology 33 (28), 3152-3161, 2015 | 257 | 2015 |
| Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity K Perica, A Tu, A Richter, JG Bieler, M Edidin, JP Schneck ACS nano 8 (3), 2252-2260, 2014 | 243 | 2014 |
| Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation RA Meyer, JC Sunshine, K Perica, AK Kosmides, K Aje, JP Schneck, ... Small (Weinheim an der Bergstrasse, Germany) 11 (13), 1519, 2015 | 196 | 2015 |
| Nanoscale artificial antigen presenting cells for T cell immunotherapy K Perica, ADL Medero, M Durai, YL Chiu, JG Bieler, L Sibener, ... Nanomedicine: Nanotechnology, Biology and Medicine 10 (1), 119-129, 2014 | 162 | 2014 |
| Enrichment and expansion with nanoscale artificial antigen presenting cells for adoptive immunotherapy K Perica, JG Bieler, C Schutz, JC Varela, J Douglass, A Skora, YL Chiu, ... ACS nano 9 (7), 6861-6871, 2015 | 151 | 2015 |
| The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles RM Samstein, K Perica, F Balderrama, M Look, TM Fahmy Biomaterials 29 (6), 703-708, 2008 | 106 | 2008 |
| Building a CAR garage: preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center K Perica, KJ Curran, RJ Brentjens, SA Giralt Biology of Blood and Marrow Transplantation 24 (6), 1135-1141, 2018 | 95 | 2018 |
| Linking form to function: Biophysical aspects of artificial antigen presenting cell design K Perica, AK Kosmides, JP Schneck Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1853 (4), 781-790, 2015 | 56 | 2015 |
| Metabolic and immunomodulatory control of type 1 diabetes via orally delivered bile-acid-polymer nanocarriers of insulin or rapamycin JS Lee, P Han, R Chaudhury, S Khan, S Bickerton, MD McHugh, HB Park, ... Nature biomedical engineering 5 (9), 983-997, 2021 | 47 | 2021 |
| Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells C Schütz, JC Varela, K Perica, C Haupt, M Oelke, JP Schneck Oncotarget 7 (42), 68503, 2016 | 33 | 2016 |
| Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia K Perica, J Flynn, KJ Curran, I Rivere, X Wang, B Senechal, E Halton, ... Leukemia 35 (11), 3268-3271, 2021 | 30 | 2021 |
| Engineering immune-evasive allogeneic cellular immunotherapies KE Martin, Q Hammer, K Perica, M Sadelain, KJ Malmberg Nature Reviews Immunology 24 (9), 680-693, 2024 | 17 | 2024 |
| Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL. K Perica, J Flynn, KJ Curran, X Wang, E Halton, C Diamonte, J Pineda, ... Journal of Clinical Oncology 37 (15_suppl), 2520-2520, 2019 | 13 | 2019 |
| Modulation of MHC binding by lateral association of TCR and coreceptor K Perica, JG Bieler, M Edidin, J Schneck Biophysical journal 103 (9), 1890-1898, 2012 | 12 | 2012 |
| Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies A Dobrin, PL Lindenbergh, Y Shi, K Perica, H Xie, N Jain, A Chow, ... Nature cancer 5 (5), 760-773, 2024 | 8 | 2024 |
| Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies Q Hammer, K Perica, RM Mbofung, H van Ooijen, KE Martin, ... Cell Stem Cell 31 (9), 1376-1386. e8, 2024 | 6 | 2024 |
Jonathan P SchneckProfessor of Pathology, Johns Hopkins School of MedicineZweryfikowany adres z jhmi.edu